The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Open accessAbstract
BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the efficacy and safety of nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, as compared with docetaxel in this patient population. METHODS: We randomly assigned 272 patients to receive nivolumab, at a dose of 3 mg per kilogram of body weight every 2 weeks, or docetaxel, at a dose of 75 mg per square meter of body-surface area every 3 weeks. The primary end point was overall survival. RESULTS: The median overall survival was 9.2 months (95% confidence interval [CI], 7.3 to 13.3) with nivolumab versus 6.0 months (95% CI, 5.1 to 7.3) with docetaxel. The risk of death was 41% lower with nivolumab than with docetaxel (hazard ratio, 0.59; 95% CI, 0.44 to 0.79; P<0.001). At 1 year, the overall survival rate was 42% (95% CI, 34 to 50) with nivolumab versus 24% (95% CI, 17 to 31) with docetaxel. The response rate was 20% with nivolumab versus 9% with docetaxel (P=0.008). The median progression-free survival was 3.5 months with nivolumab versus 2.8 months with docetaxel (hazard ratio for death or disease progression, 0.62; 95% CI, 0.47 to 0.81; P<0.001). The expression of the PD-1 ligand (PD-L1) was neither prognostic nor predictive of benefit. Treatment-related adverse events of grade 3 or 4 were reported in 7% of the patients in the nivolumab group as compared with 55% of those in the docetaxel group. CONCLUSIONS: Among patients with advanced, previously treated squamous-cell NSCLC, overall survival, response rate, and progression-free survival were significantly better with nivolumab than with docetaxel, regardless of PD-L1 expression level. (Funded by Bristol-Myers Squibb; CheckMate 017 ClinicalTrials.gov number, NCT01642004.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nivolumab has significantly improved outcomes in patients with metastatic non-small cell lung cancer (NSCLC); however, reliable prognostic biomarkers remain an unmet need.”
From SUVmax-IPI as a New Prognostic Index in Metastatic Non-Small Cell Lung Cancer Patients Receiving Nivolumab (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“The development of immune checkpoint inhibitors (ICI) targeting the PD-1/PD-L1 interaction has transformed the therapeutic landscape of patients with advanced non-small cell lung cancer (NSCLC) [1][2][3][4][5][6] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Landmark trials performed on previously treated patients with advanced NSCLC demonstrated superior overall survival (OS) with PD-1/PD-L1 blockade compared to standard chemotherapy [1][2][3] .”
From Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer (2022) · cites this paper as [2]
In the citing paper
“Although PD-L1 expression on tumor cells was correlated with treatment efficacy in melanoma patients (67, 108), it was not in patients with squamous cell carcinoma, non-small cell lung cancer and Merkel cell carcinoma (70, 72, 74).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [72]
In the citing paper
“At the data cut-off, median OS was 9.2 months (95% CI: 7.3-13.3months) on nivolumab compared with 6.0 months (95% CI: 5.1-7.3months) on docetaxel, with a 41% reduction in the risk of death in the nivolumab arm (HR 0.59, 95% CI: 0.44-0.49;P < 0.001).”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The expression of PD-L1 was neither prognostic nor predictive of clinical benefit in a retrospective analysis using various cut points in this study.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“A phase III trial (CheckMate 017) in patients previously treated for SCC compared 3 mg/kg of nivolumab given every 2 weeks with docetaxel, showing an improvement of 3.2 months [97,98]”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“In the phase III trial, nivolumab was better tolerated than docetaxel, with 85% of nivolumab patients receiving at least 90% of their planned dose intensity, compared with 69% of docetaxel patients, together with a treatment discontinuation rate of 10% versus 3% of the patients treated with nivolumab and docetaxel, respectively.”
From Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2016) · cites this paper as [98]
In the citing paper
“The primary end point was overall response rate, which occurred in 17 (14.5%) of 117 patients (95% CI 8.7 to 22.2).”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
In the citing paper
“Median time to response was 3.3 months; median duration of response had not been reached at the time of publication.”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
In the citing paper
“Adverse effects included dyspnea, fatigue, pneumonitis, diarrhea, musculoskeletal pain, and severe immune-mediated adverse effects98,99; 59% of patients experienced serious adverse events.100”
From Systemic Therapy for Stage IV Non–Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update (2015) · cites this paper as [98]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Self-citationHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Flagged first, then by citations
Research works printed but not linked: 1
- Soria JC, 2013, Eur J Cancer, 49
Cited by
Sorted by citations
Items 901–1,000 of 1,048
Master protocol trials in oncology: Review and new trial designs
Hirakawa, A., Asano, J., Sato, H., & Teramukai, S. (2018) · Contemporary Clinical Trials Communications · doi:10.1016/j.conctc.2018.08.009 · Cited by 120
Predictors of Immunotherapy-Induced Immune-Related Adverse Events
Kartolo, A., Sattar, J., Sahai, V., Baetz, T. D., & Lakoff, J. M. (2018) · Current Oncology · doi:10.3747/co.25.4047 · Cited by 119
Fujimoto, D., Yoshioka, H., Kataoka, Y., Morimoto, T., Hata, T., Kim, Y. H., Tomii, K., Ishida, T., Hirabayashi, M., Hara, S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.167 · Cited by 119
Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer
Nagano, T., TACHIHARA, M. Y., & Nishimura, Y. (2018) · Current Cancer Drug Targets · doi:10.2174/1568009619666181210114559 · Cited by 120
Recent advances in the clinical development of immune checkpoint blockade therapy
Ghahremanloo, A., Soltani, A., Modaresi, S. M. S., & Hashemy, S. I. (2019) · Cellular Oncology · doi:10.1007/s13402-019-00456-w · Cited by 119
Boku, N., Satoh, T., Ryu, M., Chao, Y., Kato, K., Chung, H. C., Chen, J., Muro, K., Kang, W. K., Yeh, K., et al. (2021) · Gastric Cancer · doi:10.1007/s10120-021-01173-w · Cited by 119
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
Drilon, A. E. D. C., Bergagnini, I., Delasos, L., Sabari, J. K., Woo, K. M., Plodkowski, A. J., Wang, L., Hellmann, M. D., Joubert, P., Sima, C. S., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw163 · Cited by 118
Immune modulation by hypofractionated stereotactic radiation therapy: Therapeutic implications
Popp, I., Grosu, A., Niedermann, G., & Duda, D. G. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.07.013 · Cited by 118
Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.007 · Cited by 118
PD-1 Modulates Radiation-Induced Cardiac Toxicity through Cytotoxic T Lymphocytes
Du, S., Zhou, L., Alexander, G. S., Park, K., Yang, L., Wang, N., Zaorsky, N. G., Ma, X., Wang, Y., Dicker, A. P., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.12.002 · Cited by 118
Regulation of PD-L1 expression by matrix stiffness in lung cancer cells
Miyazawa, A., Ito, S., Asano, S., Tanaka, I., Sato, M., Kondo, M., & Hasegawa, Y. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.12.115 · Cited by 118
Correlation between sex and efficacy of immune checkpoint inhibitors ( PD ‐1 and CTLA ‐4 inhibitors)
Wu, Y. C., Ju, Q., Jia, K., Yu, J., Shi, H. M., Wu, H., & Jiang, M. (2018) · International Journal of Cancer · doi:10.1002/ijc.31301 · Cited by 118
The immune checkpoint protein PD-L1 induces and maintains regulatory T cells in glioblastoma
DiDomenico, J. D., Lamano, J. B., Oyon, D. E., Li, Y., Veliceasa, D., Kaur, G., Ampie, L., Choy, W., Lamano, J. B., & Bloch, O. G. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1448329 · Cited by 118
Boutsikou, E., Domvri, K., Hardavella, G. F., Tsiouda, D., Zarogoulidis, P., & Kontakiotis, T. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918768238 · Cited by 118
Mekki, A., Dercle, L., Lichtenstein, P., Marabelle, A., Michot, J., Lambotte, O., Pavec, J. L., Martin, E. D., Balleyguier, C., Champiat, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.03.006 · Cited by 118
George, J., Bajaj, D., Sankaramangalam, K. P., Yoo, J. W., Joshi, N. S., Gettinger, S. N., Price, C. C., & Farrell, J. J. (2019) · Pancreatology · doi:10.1016/j.pan.2019.04.015 · Cited by 118
Shah, N. J., Al‐Shbool, G., Blackburn, M. J., Cook, M. R., Belouali, A., Liu, S. V., Madhavan, S., He, A. R., Atkins, M. B., Gibney, G. T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0771-1 · Cited by 119
Immune checkpoint inhibitor-related hepatotoxicity: A review
Remash, D., Prince, D. S., McKenzie, C. A., Strasser, S. I., Kao, S., & Liu, K. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i32.5376 · Cited by 118
Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy
Wang, Y., Du, J., Gao, Z., Sun, H., Mei, M., Wang, Y., Ren, Y., & Zhou, X. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02084-y · Cited by 118
Lequeux, A., Noman, M. Z., Xiao, M., Sauvage, D., Van Moer, K., Viry, E., Bocci, I., Hasmim, M., Bosseler, M., Berchem, G., et al. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.05.021 · Cited by 117
Proximal tubule ATR regulates DNA repair to prevent maladaptive renal injury responses
Kishi, S., Brooks, C. R., Taguchi, K., Ichimura, T., Mori, Y., Akinfolarin, A., Gupta, N., Galichon, P., Elias, B. C., Suzuki, T., et al. (2019) · Journal of Clinical Investigation · doi:10.1172/jci122313 · Cited by 117
PD-L1 expression as a potential predictive biomarker
Fusi, A., Festino, L., Botti, G., Masucci, G. V., Melero, I., Lorigan, P. C., & Ascierto, P. A. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00307-1 · Cited by 117
Ali, O. H., Diem, S., Markert, E., Jochum, W., Kerl, K., French, L. E., Speiser, D. E., Früh, M., & Flatz, L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1231292 · Cited by 117
Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors
Day, D., & Hansen, A. R. (2016) · BioDrugs · doi:10.1007/s40259-016-0204-3 · Cited by 117
Nishino, M., Ramaiya, N. H., Chambers, E. S., Adeni, A. E., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0193-2 · Cited by 117
Kim, J. H., Kim, H. S., & Kim, B. J. (2017) · Oncotarget · doi:10.18632/oncotarget.17594 · Cited by 117
Impact of prior antibiotic use on the efficacy of nivolumab for non‑small cell lung cancer
Hakozaki, T., Okuma, Y., Omori, M., & Hosomi, Y. (2019) · Oncology Letters · doi:10.3892/ol.2019.9899 · Cited by 117
Multiple sclerosis outcomes after cancer immunotherapy
García, C. R., Jayswal, R. D., Adams, V. R., Anthony, L. B., & Villano, J. L. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02060-8 · Cited by 117
Association of Stage Shift and Population Mortality Among Patients With Non–Small Cell Lung Cancer
Flores, R. M., Patel, P. B., Alpert, N., Pyenson, B. S., & Taioli, E. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.37508 · Cited by 117
Wu, J., Fu, J., Zhang, M., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0188-3 · Cited by 117
Chae, Y. K., Pan, A. P., Davis, A. A., Raparia, K., Mohindra, N. A., Matsangou, M., & Giles, F. J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.011 · Cited by 116
Clinical significance of PD-L1 and PD-L2 copy number gains in non-small-cell lung cancer
Inoue, Y., Yoshimura, K., Mori, K., Kurabe, N., Kahyo, T., Mori, H., Kawase, A., Tanahashi, M., Ogawa, H., Inui, N., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8528 · Cited by 116
Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics
Collins, D. C., Sundar, R., Lim, J. S. J., & Yap, T. A. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.10.012 · Cited by 116
Gniadek, T. J., Li, Q. K., Tully, E., Chatterjee, S., Nimmagadda, S., & Gabrielson, E. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.213 · Cited by 116
Tsao, M., Teuff, G. L., Shepherd, F. A., Landais, C., Hainaut, P. L., Filipits, M., Pirker, R., Chevalier, T. L., Graziano, S. L., Kratze, R., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx003 · Cited by 116
Noll, B., Wang, W., Gong, Y., Zhao, J., Kalhor, N., Prieto, V. G., Staerkel, G., & Roy‐Chowdhuri, S. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21987 · Cited by 116
Immune Checkpoint Inhibitors in Real‐World Treatment of Older Adults with Non–Small Cell Lung Cancer
Muchnik, E., Loh, K. P., Strawderman, M. S., Magnuson, A. M., Mohile, S. G., Estrah, V., & Maggiore, R. J. (2019) · Journal of the American Geriatrics Society · doi:10.1111/jgs.15750 · Cited by 116
Linxweiler, M., Kuo, F., Katabi, N., Lee, M., Nadeem, Z., Dalin, M. G., Makarov, V., Chowell, D., Doğan, S., Ganly, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3758 · Cited by 116
Vijayvergia, N., Dasari, A. N., Deng, M., Litwin, S., Al‐Toubah, T., Alpaugh, R. K., Dotan, E., Hall, M. J., Ross, N., Runyen, M. M., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-0775-0 · Cited by 116
ICOS Is an Indicator of T-cell–Mediated Response to Cancer Immunotherapy
Xiao, Z., Mayer, A. T., Nobashi, T. W., & Gambhir, S. S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3265 · Cited by 118
Wang, R., Yamada, T., Kita, K., Taniguchi, H., Arai, S., Fukuda, K., Terashima, M., Ishimura, A., Nishiyama, A., Tanimoto, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18442-4 · Cited by 116
Complement System: Promoter or Suppressor of Cancer Progression?
Revel, M., Daugan, M. V., Sautès‐Fridman, C., Fridman, W. H., & Roumenina, L. T. (2020) · Antibodies · doi:10.3390/antib9040057 · Cited by 116
The aging-related risk signature in colorectal cancer
Yue, T., Chen, S., Zhu, J., Guo, S., Huang, Z., Wang, P., Zuo, S., & Liu, Y. (2021) · Aging · doi:10.18632/aging.202589 · Cited by 116
Zhou, C., Huang, D., Fan, Y., Yu, X., Liu, Y., Shu, Y., Ma, Z., Wang, Z., Cheng, Y., Wang, J., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2022.09.217 · Cited by 116
Self-citationBai, X., Fisher, D. E., & Flaherty, K. T. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0204-6 · Cited by 107
Epigenetic therapy in gastrointestinal cancer: the right combination
Abdelfatah, E., Kerner, Z. J., Nanda, N., & Ahuja, N. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16644247 · Cited by 115
Broos, K., Keyaerts, M., Lecocq, Q., Renmans, D., Nguyen, T. T., Escors, D., Liston, A., Raes, G., Breckpot, K., & Devoogdt, N. (2017) · Oncotarget · doi:10.18632/oncotarget.16708 · Cited by 115
Shiroyama, T., Suzuki, H., Tamiya, M., Tamiya, A., Tanaka, A., Okamoto, N., Nakahama, K., Taniguchi, Y., Isa, S., Inoue, T., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.1234 · Cited by 115
Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy
Ahern, E. S., Smyth, M. J., Dougall, W. C., & Teng, M. W. L. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0095-y · Cited by 115
Update on PD-1/PD-L1 Inhibitors in Multiple Myeloma
Jelı́nek, T., Paiva, B., & Hájek, R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02431 · Cited by 115
Zha, H., Wang, X., Zhu, Y. J., Chen, D., Han, X., Yang, F., Gao, J., Hu, C., Shu, C., Feng, Y., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0272 · Cited by 115
Fujita, K., Kim, Y. H., Kanai, O., Yoshida, H., Mio, T., & Hirai, T. (2018) · Respiratory Medicine · doi:10.1016/j.rmed.2018.11.021 · Cited by 115
Negrao, M. V., Lam, V. K. L., Reuben, A., Rubin, M. L., Landry, L. L., Roarty, E. B., Rinsurongkawong, W., Lewis, J., Roth, J. A., Swisher, S. G., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.02.008 · Cited by 115
Khan, M. B., Lin, J., Liao, G., Tian, Y., Liang, Y., Li, R., Liu, M., & Yuan, Y. (2018) · Medicine · doi:10.1097/md.0000000000011936 · Cited by 115
Alborelli, I., Leonards, K., Rothschild, S. I., Leuenberger, L. P., Prince, S. S., Mertz, K. D., Poechtrager, S., Buess, M., Zippelius, A., Laubli, H. P., et al. (2019) · The Journal of Pathology · doi:10.1002/path.5344 · Cited by 116
Ho, T. T. B., Nasti, A., Seki, A., Komura, T., Inui, H., Kozaka, T., Kitamura, Y., Shiba, K., Yamashita, T., Yamashita, T., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001367 · Cited by 116
Sorensen, S. F., Demuth, C., Weber, B., Sørensen, B. S., & Meldgaard, P. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.08.001 · Cited by 114
The next generation of immunotherapy: keeping lung cancer in check
Somasundaram, A., & Burns, T. F. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0456-5 · Cited by 114
PD-1/PD-L1 pathway inhibitors in advanced prostate cancer
Velho, P. I., & Antonarakis, E. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1464388 · Cited by 114
O’Connor, J. M., Fessele, K. L., Steiner, J., Seidl-Rathkopf, K., Carson, K. R., Nussbaum, N. C., Yin, E. S., Adelson, K. B., Presley, C. J., Chiang, A. C., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.0798 · Cited by 114
Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations
Toki, M. I., Mani, N. L., Smithy, J. W., Liu, Y., Altan, M., Wasserman, B. E., Tuktamyshov, R., Schalper, K. A., Syrigos, K. N., & Rimm, D. L. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.09.012 · Cited by 114
van Holstein, Y., Kapiteijn, E., Bastiaannet, E., van den Bos, F., Portielje, J. E. A., & de Glas, N. A. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00697-2 · Cited by 114
Fukihara, J., Sakamoto, K., Koyama, J., Ito, T., Iwano, S., Morise, M., Ogawa, M., Kondoh, Y., Kimura, T., Hashimoto, N., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.07.006 · Cited by 114
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 115
Liu, C., Chen, Z., Chen, K., Liao, F.-T., Chung, C.-E., Liu, X., Lin, Y., Keohavong, P., Leikauf, G. D., & Di, Y. P. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-1994 · Cited by 114
Mollaei, M., Hassan, Z. M., Khorshidi, F., & Langroudi, L. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101056 · Cited by 114
der Welle, C. M. C., Verschueren, M. V., Tonn, M., Peters, B. J. M., Schramel, F. M. N. H., Klungel, O. H., Groen, H. J. M., van de Garde, E. M. W., The Santeon NSCLC Study Group, Kastelijn, E. A., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-85696-3 · Cited by 114
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 116
Sholl, L. M., Aisner, D. L., Allen, T. C., Beasley, M. B., Borczuk, A., Cagle, P. T., Capelozzi, V. L., Đačić, S., Hariri, L. P., Kerr, K. M., et al. (2016) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2015-0506-sa · Cited by 113
Murakami, N., Borges, T. J., Yamashita, M., & Riella, L. V. (2016) · Clinical Kidney Journal · doi:10.1093/ckj/sfw024 · Cited by 113
Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity
Mittica, G., Ghisoni, E., Giannone, G., Aglietta, M., Genta, S., & Valabrega, G. (2017) · Oncotarget · doi:10.18632/oncotarget.20042 · Cited by 113
Berger, K., & Pu, J. J. (2017) · Gene · doi:10.1016/j.gene.2017.09.050 · Cited by 113
The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Botticelli, A., Onesti, C. E., Zizzari, I. G., Cerbelli, B., Sciattella, P., Occhipinti, M. A., Roberto, M., Pietro, F. R. D., Bonifacino, A., Ghidini, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22242 · Cited by 113
Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC)
Schmid, S., Diem, S., Li, Q., Krapf, M., Flatz, L., Leschka, S., Desbiolles, L. M., Klingbiel, D., Jochum, W., & Früh, M. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2239-4 · Cited by 113
Meyo, M. T., Jouinot, A., Leprieur, E. G., Fabre, E., Wislez, M., Alifano, M., Leroy, K., Boudou, P., Tlemsani, C., Khoudour, N., et al. (2020) · Cancers · doi:10.3390/cancers12020473 · Cited by 113
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Ciciola, P., Cascetta, P., Bianco, C., Formisano, L., & Bianco, R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9030675 · Cited by 113
Yang, Y., Li, L., Jiang, Z., Wang, B., & Pan, Z. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02641-5 · Cited by 113
Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions
Pansy, K., Uhl, B., Krstić, J., Szmyra, M., Fechter, K., Santiso, A., Thüminger, L., Greinix, H., Kargl, J., Prochazka, K. T., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222413311 · Cited by 113
Mukherjee, S., Mukherjee, S., Abourehab, M. A. S., Sahebkar, A., & Kesharwani, P. (2022) · European Polymer Journal · doi:10.1016/j.eurpolymj.2022.111471 · Cited by 113
Yin, X., Liao, H., Hong, Y., Lin, N., Li, S., Xiang, Y., & Ma, X. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.002 · Cited by 113
Combinatorial Cancer Immunotherapies
Hellmann, M. D., Friedman, C. F., & Wolchok, J. D. (2016) · Advances in immunology · doi:10.1016/bs.ai.2015.12.005 · Cited by 112
Toxicity management of immunotherapy for patients with metastatic melanoma
Linardou, H., & Gogas, H. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.10 · Cited by 112
Adams, D. L., Adams, D. K., He, J., Kalhor, N., Zhang, M., Xu, T., Gao, H., Reuben, J. M., Qiao, Y., Komaki, R. R., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0802 · Cited by 112
Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade
Reynolds, K. L., Thomas, M. F., & Dougan, M. L. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0174 · Cited by 112
Grassadonia, A., Sperduti, I., Vici, P., Iezzi, L., Brocco, D., Gamucci, T., Pizzuti, L., Maugeri‐Saccà, M., Marchetti, P., Cognetti, G., et al. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120542 · Cited by 112
The promise of Immuno-oncology: implications for defining the value of cancer treatment
Kaufman, H. L., Atkins, M. B., Subedi, P., Wu, J. J., Chambers, J. D., Mattingly, T. J., Campbell, J. D., Allen, J., Ferris, A. E., Schilsky, R. L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0594-0 · Cited by 112
Pulmonary complications of immune checkpoint inhibitors in patients with nonsmall cell lung cancer
Cadranel, J. L., Canellas, A., Matton, L., Darrason, M., Parrot, A., Naccache, J., Lavolé, A., Ruppert, A.-M., & Fallet, V. (2019) · European Respiratory Review · doi:10.1183/16000617.0058-2019 · Cited by 113
Vokes, N. I., Liu, D., Ricciuti, B., Jimenez-Aguilar, E., Rizvi, H. A., Dietlein, F., He, M., Margolis, C. A., Elmarakeby, H., Girshman, J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00171 · Cited by 112
Hellmann, M. D., Bivi, N., Calderón, B., Shimizu, T., Delafontaine, B., Liu, Z. T., Szpurka, A. M., Copeland, V., Hodi, F. S., Rottey, S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3716 · Cited by 112
Zheng, Z., Wieder, T., Mauerer, B., Schäfer, L., Kesselring, R., & Braumüller, H. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411673 · Cited by 113
Grossi, F., Crinò, L., Logroscino, A., Canova, S., Delmonte, A., Melotti, B., Proto, C., Gelibter, A., Cappuzzo, F., Turci, D., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.05.015 · Cited by 111
Self-citationPD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
Scheel, A. H., Ansén, S., Schultheis, A. M., Scheffler, M., Fischer, R. N., Michels, S., Hellmich, M., George, J., Zander, T., Brockmann, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1131379 · Cited by 111
Characteristics and Clinical Outcomes of Sarcomatoid Carcinoma of the Lung
Ung, M., Rouquette, I., Filleron, T., Taillandy, K., Brouchet, L., Bennouna, J., Delord, J., Milia, J., & Mazières, J. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.001 · Cited by 111
Next generation predictive biomarkers for immune checkpoint inhibition
Khagi, Y., Kurzrock, R., & Patel, S. P. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9652-y · Cited by 111
Development of CAR T cells designed to improve antitumor efficacy and safety
Jaspers, J. E., & Brentjens, R. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.012 · Cited by 111
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 113
Wang, Y., Zhang, T., Huang, Y., Li, W., Zhao, J., Yang, Y., Li, C., Wang, L., & Bi, N. (2021) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2021.12.150 · Cited by 111
Leal, T. A. B., Kotecha, R. R., Ramlau, R., Zhang, L., Milanowski, J., Cobo, M., Roubec, J., Petruzelka, L. B., Havel, L., Kalmadi, S. R., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00344-3 · Cited by 119
Self-citationImmuno-oncology combinations: raising the tail of the survival curve
Harris, S. J., Harris, S. J., Brown, J. S., Lopez, J. S., Yap, T. A., Brown, J. S., Lopez, J. S., & Yap, T. A. (2016) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2016.0015 · Cited by 110
Nomizo, T., Ozasa, H., Tsuji, T., Funazo, T. Y., Yasuda, Y., Yoshida, H., Yagi, Y., Sakamori, Y., Nagai, H., Hirai, T., et al. (2017) · Scientific Reports · doi:10.1038/srep45124 · Cited by 110
Metadata
- Authors
- Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., Waterhouse, D., Ready, N., Gainor, J., Arén Frontera, O., Havel, L., Steins, M., Garassino, M. C., Aerts, J. G., Domine, M., Paz-Ares, L., Reck, M., Baudelet, C., Harbison, C. T., Lestini, B., & Spigel, D. R.
- Affiliations
- City Of Hope National Medical Center (US)
- The Netherlands Cancer Institute (NL)
- University of Perugia (IT)
- Ruhrlandklinik (DE)
- Russian Cancer Research Center NN Blokhin (RU)
- Moffitt Cancer Center (US)
- University of Chicago (US)
- Oncology Hematology Care (US)
- Duke Medical Center (US)
- Massachusetts General Hospital (US)
- Fakultní nemocnice Bulovka (CZ)
- University Hospital Heidelberg (DE)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Amphia Ziekenhuis (NL)
- Hospital Universitario Virgen del Rocío (ES)
- LungenClinic Grosshansdorf (DE)
- Bristol-Myers Squibb (United States) (US)
- Tennessee Oncology (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-09
- Volume
- 373
- Issue
- 2
- Pages
- 123-135
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4681400
- OpenAlex
- W2156353875
- Cited by
- 8,447
- References
- 22
- Citations by year
- 2026: 204 · 2025: 332 · 2024: 525 · 2023: 627 · 2022: 718 · 2021: 928 · 2020: 1065 · 2019: 969 · 2018: 1066 · 2017: 1001 · 2016: 803 · 2015: 184
- FWCI
- 444.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- National Cancer Institute (P30CA076292)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- nivolumab, docetaxel, squamous cell non-small cell lung cancer, PD-1 inhibitors, immune checkpoint inhibitors, overall survival, progression-free survival, PD-L1 expression, treatment-related adverse events, second-line therapy, previously treated patients, response rate, treatment safety and efficacy comparison, immunotherapy versus chemotherapy
- MeSH terms
- Docetaxel, Nivolumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Female, Humans, Immunoglobulin G, Lung Neoplasms, Male, Middle Aged, Survival Analysis, Taxoids, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
